United States: Orphan Exclusivity In Catalyst's Aftermath: FDA Inaction Leaves Rare Disease Sponsors In Limbo - Mayer Brown

More than a year has passed since the US Court of Appeals for the Eleventh Circuit's decision in Catalyst Pharms., Inc. v. Becerra struck down the US Food and Drug Administration's (FDA)...